Biophytis SA

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign

A panel of drug developers, investors and advisors discussed the merits of going public in the US through an initial public offering or through a merger with a special purpose acquisition corporation

Initial public offerings may have gotten off to a slow start with only three IPOs in January, but 10 drug developers went public in the US between 3 and 5 February raising a total of $1.9bn, including

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. OncoSec